ONESOURCE vs PPLPHARMA: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. ONESOURCE SPECL PHARMA L shows a higher ROE, faster revenue growth and lower leverage, while PIRAMAL PHARMA shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ONESOURCE leads 8; PPLPHARMA leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ONESOURCE | PPLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ONESOURCE | PPLPHARMA |
|---|---|---|
| Live Price | ₹1,592.2 | ₹211.35 |
| Day Change | 3.26% | -0.54% |
| Volume | 9.19 L | 34.09 L |
| 52-Week High | ₹1,925 | ₹231.93 |
| 52-Week Low | ₹1,057 | ₹132.3 |
| Distance from 52W High | -17.29% | -8.87% |
Valuation
| Metric | ONESOURCE | PPLPHARMA |
|---|---|---|
| Market Cap | ₹18,225 Cr | ₹28,211 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 3.12x | 3.45x |
| EPS | ₹4.47 | ₹0.85 |
| Book Value | ₹508.64 | ₹61.31 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | ONESOURCE | PPLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0.5% | -0.1% |
| EPS Growth (TTM YoY) | -95.3% | 0% |
| Qtr Sales Growth | -0.57% | -50.44% |
| Qtr Profit Growth | 104.92% | 263.54% |
Profitability & Leverage
| Metric | ONESOURCE | PPLPHARMA |
|---|---|---|
| ROE | 0.36% | -3.99% |
| ROCE | 1.97% | 0.86% |
| Net Margin | -5.19% | -3.68% |
| Operating Margin | 10.09% | 1.21% |
| Debt to Equity | 0.21x | 0.67x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ONESOURCE | PPLPHARMA |
|---|---|---|
| Promoter Holding | 30.48% | 34.8%▼ 0.06 pp |
| FII Holding | 19.19%▲ 1.69 pp | 12.52%▼ 17.66 pp |
| DII Holding | 23.38%▲ 2.77 pp | 14.57%▼ 1.04 pp |
| Public Holding | 26.94%▼ 4.47 pp | 37.63%▲ 18.62 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ONESOURCE SPECL PHARMA L and PIRAMAL PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.